• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Novacyt S.A. (Alternext: ALNOV)

The Novacyt Group is a leader in the field of diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NovaPrep®, and a strong international network provided by Lab21, its UK diagnostics subsidiary, it is able to provide an extensive range of oncology and infectious disease products globally. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its customers and partners include major corporates. *

 

	Start	2006-07-11 established
	Group	Novacyt (Group)
	Industry	laboratory equipment and instruments
	Industry 2	diagnostics (medical/biological)
	Person	Mullis, Graham (Novacyt 201409 CEO before Lab21 CEO)
	Person 2	Dyer, Anthony (Novacyt 201409– Finance Director before part time Group Financial Controller)
	Region	Paris
	Country	France
	Street	13 Avenue Morane Saulnier
	City	78140 Vélizy-Villacoublay
	Tel	+33-1-3946-5104
		Address record changed: 2015-09-13
Basic data	Employees	D: 101 to 500 (2017-12-31)
	Currency	EUR
	Annual sales	14,954,000 (revenue, consolidated (2017) 2017-12-31)
	Profit	-4,071,000 (2017-12-31)
	Cash	4,300,000 (2017-12-31)
		* Document for �About Section�: Novacyt S.A.. (9/17/14). "Press Release: Novacyt Appoints Anthony Dyer as Finance Director". Paris & Cambridge.
		Record changed: 2018-10-31

Advertisement

More documents for Novacyt (Group)

• [1] Novacyt S.A.. (9/26/18). "Press Release: Novacyt Half Year 2018 Results. Molecular Product Revenues up 18% to €3m – Gross Margin Increases to 64%". Paris & Camberley....
• [2] Novacyt S.A.. (9/13/18). "Press Release: Novacyt Partners with Applied Microarrays in Assay Design". Paris & Camberley....
• [3] Novacyt S.A.. (4/26/18). "Press Release: Novacyt Full Year 2017 Results". Paris & Camberley....
• [4] Novacyt S.A.. (10/18/17). "Press Release: Proposed Admission to Trading on AIM and Successful Capital Riase of €9.7 Million [Not for US, AU, CA, JP or ZA or any other jurisdiction where unlawful]". Paris & Cambridge....
• [5] Novacyt S.A.. (7/20/17). "Press Release: Novacyt Revenues Half Year 2017". Paris & Cambridge....
• [6] Novacyt S.A.. (6/20/17). "Press Release: Novacyt Successfully Completes €3.0M Fundraising". Paris & Cambridge....
• [7] Novacyt S.A.. (4/27/17). "Press Release: Novacyt Full Year 2016 Results". Paris & Cambridge....
• [8] Novacyt S.A.. (4/6/17). "Press Release: Novacyt Announces Bond Issue". Paris & Cambridge....
• [9] Novacyt S.A.. (12/15/16). "Press Release: Novacyt Successfully Completes €2.7m Fundraising". Paris & Cambridge....
• [10] Novacyt S.A.. (7/20/16). "Press Release: Novacyt Half Year 2016 Revenues. Continued Strong Growth in Novaprep Sales – Strong Growth from the Acquisition of Primerdesign". Paris & Cambridge....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.